aweinsoff@channelchek.com, Author at Channelchek

Release – Noble Capital Markets Initiates Equity Research Coverage on Twin Hospitality Group Inc.

Posted on October 22, 2025October 22, 2025 by [email protected]

October 22, 2025

DALLAS, Oct. 22, 2025 (GLOBE NEWSWIRE) — Twin Hospitality Group Inc. (“Twin Hospitality”) (Nasdaq: TWNP), the parent company of Twin Peaks Restaurant and Smokey Bones, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Senior Research Analyst, Joe Gomes, as well as news and advanced market data on Twin Hospitality, is available on Channelchek.

FAT Brands Inc. (NASDAQ: FAT) served as the parent company that executed the strategic spin-out of Twin Hospitality Group earlier this year, separating its Twin Peaks and Smokey Bones restaurant brands into Twin Hospitality Group Inc.

About Twin Hospitality Group Inc.:

Twin Hospitality Group Inc. (NASDAQ: TWNP) is a restaurant company that strategically develops, operates, and franchises specialty casual dining restaurant concepts with a goal of redefining the casual dining category with its experiential-driven brands, Twin Peaks and Smokey Bones. Twin Peaks, known as the ultimate sports lodge, is an award-winning restaurant and sports bar brand with 114 locations across 27 states and Mexico and is known for its made-from-scratch food, 29-degree draft beer, innovative cocktail program and sports on wall-to-wall televisions. Smokey Bones is a full-service, meat-centric restaurant brand and concept with 45 locations, across 15 states specializing in ribs and a variety of other slow-smoked, fire-grilled and seared meats, along with a full bar. For more information, please visit www.twinpeaksrestaurant.com.

About Noble Capital Markets:

Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. We deliver middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.

About Channelchek:

Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public emerging growth and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.

Investor Relations:
ICR
Michelle Michalski
[email protected]

Media Relations:
Erin Mandzik
[email protected]
860-212-6509

Release – Sky Harbour Announces Q2 Results; Opening of New Campus in Centennial Airport, Denver, CO; Updates on Leasing, Construction and Other Activities; Reiterates Prior Guidance for 2025

Posted on October 21, 2025October 21, 2025 by [email protected]

Research News and Market Data on SKYH

08/12/2025

WEST HARRISON, N.Y.–(BUSINESS WIRE)– Sky Harbour Group Corporation (NYSE: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation infrastructure company building the first nationwide Home Base Operator (HBO) network of campuses for business aircraft, announced the release of its unaudited financial results for the three months ended June 30, 2025 on Form 10-Q. The Company also announced the filing of its unaudited financial results for the three months ended June 30, 2025 for Sky Harbour Capital (Obligated Group) with MSRB/EMMA. Please see the following links to access the filings:

SEC 10-Q:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001823587/000143774925026180/ysac20250630_10q.htm

MSRB/EMMA:

https://emma.msrb.org/P21953654-P21491522-P21943258.pdf

Financial Highlights on a Consolidated Basis include:

Constructed assets and construction in progress reached over $295 million at quarter end, an increase of $125 million year-over-year and $18 million as compared to the prior quarter.
Q2 2025 consolidated revenues increased 82% as compared to Q2 2024 and 18% as compared to the prior quarter.
Net cash used in operating activities was approximately $0.9 million for the quarter, a significant improvement from the $5 million used in prior quarter.
Strong liquidity and capital resources as of June 30th, 2025, with consolidated cash and US Treasuries totaling nearly $75 million.
Reiterating our guidance of reaching operating cash-flow breakeven on a consolidated run-rate basis by year-end 2025, supported by the commencement of revenues from campuses in Phoenix, Denver, Dallas and Seattle.

Financial Highlights at Sky Harbour Capital (Obligated Group) include:

Q2 2025 Obligated Group Revenues increased approximately 20% as compared to the prior quarter.
Net cash from operating activities (positive) reached approximately $2.2 million in Q2 2025, a 117% increase from the prior quarter.
Cash and US Treasuries at the Obligated Group totaled $37 million as of June 30^th, 2025.

Update on Site Acquisition

Sky Harbour currently has campuses operating at Houston’s Sugar Land Regional Airport (SGR), Nashville International Airport (BNA), Miami Opa-Locka Executive Airport (OPF), San Jose Mineta International Airport (SJC), Camarillo Airport (CMA), Phoenix Deer Valley Airport (DVT), Dallas’s Addison Airport (ADS), Seattle’s King County International Airport – Boeing Field (BFI); one campus nearing construction completion at Denver’s Centennial Airport (APA); campuses in pre-development at Chicago Executive Airport (PWK), Sky Harbour’s first four New-York-metro area airports – Bradley International Airport (BDL), Hudson Valley Regional Airport (POU), Trenton-Mercer Airport (TTN), and Stewart International Airport (SWF); Orlando Executive Airport (ORL), Dulles International Airport (IAD), Salt Lake City International Airport (SLC), and Portland-Hillsboro Airport (HIO).
We reiterate our prior guidance of five additional airport ground leases to be announced by the end of 2025, for a total portfolio of 23 airports by year end.

Update on Construction and Development Activities, Change in Development Leadership

As reported on our monthly activity reports filed with MSRB/EMMA, and available on our website, Dallas Addison (ADS) achieved its first Certificates of Occupancy in Q2 and has commenced resident flight operations. Denver Centennial (APA) achieved its first Certificates of Occupancy last month and will commence resident flight operations in the coming weeks. Please see the following link for the last monthly construction report:

https://emma.msrb.org/P21941616-P21483179-P21934207.pdf

Miami Opa Locka (OPF) Phase 2 commenced construction in Q2 and is expected to be completed by Q2 2026.
Outgoing COO, Will Whitesell, who led the Company’s construction division, has entered an amicable separation agreement with the Company and has assisted in an orderly transfer of his responsibilities. The Company is grateful for Will’s commitment and his contributions and wishes him much success in his future endeavors.
Phil Amos, a 40-year veteran of the Pre-Engineered Metal Building (PEMB) industry, and co-founder of A&F Contractors, has joined Sky Harbour as Head of Construction and President of Sky Harbour’s newly-formed, wholly-owned development subsidiary, Ascend Aviation Services (“Ascend”). Ascend brings specialized airport construction-management and in-house General Contracting capabilities to Sky Harbour. Ascend is headquartered in Houston, TX, and staffed by veterans of the airport construction industry around the United States, including legacy members of the Sky Harbour development team. In addition to its construction management and general contracting functions, Ascend oversees the operations of Stratus Building Systems, Sky Harbour’s wholly-owned PEMB manufacturing subsidiary. Ascend and Stratus together constitute a vertically-integrated, specialized airport infrastructure developer. Mr. Amos, while at A&F, served as the general contractor for Sky Harbour’s first hangar campus at Sugar Land Regional Airport, which was delivered on time and under budget.

Update on Leasing Activities

Stabilized campuses: The Company continues to enjoy higher-than-forecast revenue per square foot at its stabilized campuses. Revenue per square foot continues to grow as legacy hangar leases turn or are renewed.
New campuses: The Company has executed the first six hangar leases at its new Denver, Dallas and Phoenix campuses, and is under LOI for additional leases. The Company expects to meet its revenue run-rate targets at the new campuses within six months.
Pre-leasing: The Company has initiated a pilot project at two airports – Bradley International Airport (BDL) and Dulles International Airport (IAD) to pre-lease hangar space prior to construction commencement. The objective is to take advantage of growing awareness of the Sky Harbour HBO value proposition within the US Business Aviation industry to a) reduce lease-up times, b) better curate resident communities, and c) integrate customized resident improvements during construction (as opposed to retrofitting). Hangar leases have been executed at both airports at revenue rates that present an introductory pricing advantage to pre-lease residents while still delivering above-target per-square-foot revenue to the Company. Additional pre-leases are under LOI.

Update on Airport Operations

As of Q3, the Company is conducting flight operations at nine airports.
Under the leadership of Marty Kretchman, Senior Vice President of Airports, the company has transitioned to a centralized operating model, featuring National Directors of Line Training; Facilities; and Ground Support Equipment (GSE).
Surveys of current residents indicate that Sky Harbour’s HBO service offering has become a key differentiating component of the Sky Harbour value proposition. The Company plans to continue to invest in constant improvement in airfield operations, through selective recruiting, rigorous training, detailed and thoughtful operating procedures, and constant innovation in collaboration with Sky Harbour residents.

Update on Capital Formation

After several quarters of “dual tracking” the review of various debt funding alternatives and proposals, the Company has decided to pursue a tax-exempt bank debt facility in lieu of a bond issue.
We are currently in advanced discussions with a major US financial institution for an expected five (5) year drawdown construction facility of $200 million, with an expected indicative interest rate of 80% of 3-month SOFR plus 200 basis points (~5.47% in the current market).
Our debt financing plan is to fund the next 5-6 airport projects using this facility and internal equity. The Company expects to replace this facility with permanent tax-exempt bonds in the next 3-4 years. We expect to close the facility on or about August 28^th. However, we can provide no assurance on exact terms or the timing of this facility.

Tal Keinan commented: “As Sky Harbour navigates the transition from a tactical team, emphasizing agility, innovation and flexibility, to a high-growth organization, increasingly embracing process, discipline and specialization, five constants will continue to guide our leadership: 1) Obsessive focus on the Resident, 2) Commitment to building long-term shareholder value, 3) Uncompromising pursuit of professional excellence, 4) Cost-efficiency, and 5) Individual ownership of results. We value the reputation we are building in business aviation and intend to continue building it for years to come.”

About Sky Harbour

Sky Harbour Group Corporation is an aviation infrastructure company developing the first nationwide network of Home-Basing campuses for business aircraft. The company develops, leases, and manages general aviation hangar campuses across the United States. Sky Harbour’s Home-Basing offering aims to provide private and corporate residents with the best physical infrastructure in business aviation, coupled with dedicated service, tailored specifically to based aircraft, offering the shortest time to wheels-up in business aviation. To learn more, visit www.skyharbour.group.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements about the financial condition, results of operations, earnings outlook and prospects of SHG, including statements regarding our expectations for future results, our expectations for future ground leases, our expectations on future construction and development activities and lease renewals, and our plans for future financings. When used in this press release, the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on the current expectations of the management of Sky Harbour Group Corporation (the “Company”) as applicable and are inherently subject to uncertainties and changes in circumstances. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. For more information about risks facing the Company, see the Company’s annual report on Form 10-K for the year ended December 31, 2024 and other filings the Company makes with the SEC from time to time. The Company’s statements herein speak only as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Key Performance Indicators

We use a number of metrics, including annualized revenue run rate per leased rentable square foot, to help us evaluate our business, measure our performance, identify trends affecting our business, formulate business plans, and make strategic decisions. Our key performance indicators may be calculated in a manner different than similar key performance indicators used by other issuers. These metrics are estimated operating metrics and not projections, nor actual financial results, and are not indicative of current or future performance.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250812166353/en/

Sky Harbour Investor Relations: [email protected] Attn: Francisco X. Gonzalez

Source: Sky Harbour Group Corporation

Release – Vince Holding Corp. Debuts on Nasdaq

Posted on October 21, 2025October 21, 2025 by [email protected]

Research News and Market Data on VNCE

10/21/2025

Will Commemorate Milestone by Ringing the Nasdaq Closing Bell on October 23, 2025

NEW YORK–(BUSINESS WIRE)– Vince Holding Corp., (Nasdaq: VNCE) (“VNCE” or the “Company”), a global contemporary retailer, will begin trading today on The Nasdaq Stock Market LLC (“Nasdaq”) following its voluntary transfer from the New York Stock Exchange under the ticker symbol “VNCE”. To celebrate this milestone, the Company will ring the Nasdaq Closing Bell on October 23, 2025.

“We are thrilled to begin this exciting new chapter on Nasdaq—a milestone that celebrates both our incredible team and our company’s distinguished legacy of delivering understated luxury and timeless quality to customers,” said Brendan Hoffman, Chief Executive Officer of VNCE. “This transition reflects our continued growth trajectory as we remain on track with our objectives and continue to see nice momentum across the business today as we execute on our strategic vision. We couldn’t be more proud to ring the Nasdaq Closing Bell and showcase the remarkable transformation and the bright future we have ahead.”

The Nasdaq Closing Bell ceremony will be broadcast live starting at approximately 3:45 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. A live stream of the Nasdaq Closing Bell will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony under Bell Ceremony Events at the bottom of the page.

ABOUT VINCE HOLDING CORP.
Vince Holding Corp. is a global retail company that operates the Vince brand women’s and men’s ready to wear business. Vince, established in 2002, is a leading global luxury apparel and accessories brand best known for creating elevated yet understated pieces for every day effortless style. Vince Holding Corp. operates 46 full-price retail stores, 14 outlet stores, and its e-commerce site, vince.com, as well as through premium wholesale channels globally. Please visit www.vince.com for more information.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identifiable by use of the words “may,” “believe,” “expect,” “intend,” “plan to,” “estimate,” “project” or similar expressions. Investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risk and uncertainties. Though we believe that expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectation will prove to be correct. Actual results may differ materially from the forward-looking statements as a result of various factors. These and other risk factors are discussed in the Company’s filings with the Securities and Exchange Commission, including those set forth under “Risk Factors” and “Disclosures Regarding Forward-Looking Statements” in our Annual Report on Form 10-K for the year ended February 1, 2025 and, if applicable, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. All forward-looking statements included in this press release are expressly qualified in their entirety by such cautionary statements. We expressly disclaim any obligation to update, amend or clarify any forward-looking statement to reflect events, new information or circumstances occurring after the date of this press release except as required by applicable law.

Investor Relations:
ICR, Inc.
Caitlin Churchill, 646-277-1274
[email protected]

Source: Vince Holding Corp.

Release – Century Lithium Produces Lithium Hydroxide at Demonstration Plant in Nevada

Posted on October 20, 2025October 20, 2025 by [email protected]

Research News and Market Data on CYDVF

October 20, 2025 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to announce that the Company’s Lithium Extraction Facility (“Demonstration Plant”) in Amargosa Valley, Nevada, USA, has produced for its first time lithium hydroxide from lithium carbonate derived from the Company’s 100%-owned Angel Island lithium project, located near Silver Peak, Nevada.

“The lithium hydroxide samples produced by our team represent another important milestone for the Company,” said Bill Willoughby, President and CEO of Century Lithium. “Up until this point, Century’s efforts have focused on making lithium carbonate as the end product for Angel Island. By producing high-purity lithium hydroxide, we show that Angel Island can supply another major lithium product for the domestic market.”

The lithium hydroxide samples were produced from lithium carbonate derived from Angel Island’s lithium claystone deposit and treated at the Demonstration Plant using Century Lithium’s patent-pending alkaline leach and Direct Lithium Extraction (“DLE”) process. The lithium hydroxide samples were produced on-site in a batch process using conventional liming conversion with calcium hydroxide to make high-purity, +99.5% lithium hydroxide.

The Company is also pursuing a direct lithium conversion (“DLC”) process to produce lithium hydroxide directly from lithium chloride solution. Such a process would thereby bypass lithium carbonate as an intermediate stage, simplify operations, and reduce energy consumption and operating costs.

With the demand for mobile and stationary energy storage growing, Century Lithium’s project at Angel Island is strategically positioned as the United States seeks a reliable domestic source of critical materials. Lithium carbonate is an essential component for LFP batteries, while lithium hydroxide is needed for high-energy-density NMC/NCA batteries. By demonstrating the potential to produce both, Angel Island stands out as a potential key contributor to American energy independence and a resilient battery supply chain.

Qualified Person

Todd Fayram, MMSA-QP and Senior Vice President, Metallurgy of Century Lithium is the qualified person as defined by National Instrument 43-101 and has approved the technical information in this release.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium company, focused on developing its 100%-owned lithium project Angel Island in Esmeralda County, Nevada, which hosts one of the largest sedimentary lithium deposits in the United States. The Company has utilized its patent-pending process for chloride leaching combined with direct lithium extraction to make battery-grade lithium carbonate product samples from Angel Island’s lithium-bearing claystone at its Demonstration Plant in Amargosa Valley, Nevada.

Angel Island is one of the few advanced lithium projects in development in the United States to provide an end-to-end process to produce battery-grade lithium carbonate for the growing electric vehicle and battery storage market. Angel Island is currently in the permitting stage for a three-phase feasibility-level production plan, expected to yield an estimated life-of-mine average of 34,000 tonnes per year of lithium carbonate over a 40-year mine-life.

Century Lithium trades on both the TSX Venture Exchange under the symbol “LCE” and the OTCQX under the symbol “CYDVF”, and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development and value of the Project and benefits associated therewith, statements with respect to the expected project economics for the Project, such as estimates of life of mine, lithium prices, production and recoveries, capital and operating costs, IRR, NPV and cash flows, any projections outlined in the Feasibility Study in respect of the Project, the permitting status of the Project and the Company’s future development plans.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be under the Company’s profile at www.sedarplus.com. The Company expressly disclaims any obligation to update forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Release – GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025

Posted on October 16, 2025October 16, 2025 by [email protected]

Research News and Market Data on GOVX

Presentations Underscore Favorable Safety Profile and Robust T-Cell Responses of GEO-CM04S1 in Vulnerable Populations

ATLANTA, GA – October 16, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced presentations by its senior scientific leadership at the World Vaccine Congress Europe 2025, held October 13–16 at the RAI Amsterdam Convention Centre in Amsterdam, Netherlands.

Presentation Highlights

Mark J. Newman, PhD – Chief Scientific Officer
Workshop Presentation: “Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity – Broader specificity – Increased memory.”

Highlighted the limitations of current “one-size-fits-all” vaccines for immunocompromised populations.
Presented Phase 2 data showing GEO-CM04S1 elicits strong T-cell responses to both Spike (S) and Nucleocapsid (N), exceeding responses induced by mRNA boosters.
Demonstrated broad, durable immunity in preclinical and early clinical data, including responses against Omicron subvariants.
Reinforced the potential of GEO-CM04S1 to provide longer-lasting protection and reduce the need for frequent vaccine reformulations.

Kelly T. McKee, Jr., MD, MPH – Chief Medical Officer
Poster Presentation: “Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies.”

Reported interim safety results from a Phase 2 trial in patients with hematologic malignancies post-hematopoietic stem cell transplant or chimeric antigen receptor (CAR)-T cell therapy.
GEO-CM04S1 showed a safety profile comparable to mRNA vaccines, with only mild-to-moderate treatment-emergent adverse events, predominantly injection site reactions, fatigue, and myalgia… observed.
No vaccine-related serious adverse events, myocarditis, or pericarditis have been reported to date.
Breakthrough infections occurred but were mild-to-moderate in severity.

“These data continue to support our conviction that GEO-CM04S1 has the potential to fill a critical gap for immunocompromised patients who are not adequately protected against severe COVID-19 by existing vaccines,” said David Dodd, Chairman & CEO of GeoVax. “Our MVA-based, multi-antigen approach is designed to provide broader, more durable protection, and we are encouraged by the consistent safety profile emerging across the ongoing trials.”

About GEO-CM04S1

GEO-CM04S1 is a synthetic, next-generation COVID-19 vaccine candidate that co-expresses spike (S) and nucleocapsid (N) antigens using GeoVax’s MVA vector platform. Designed to induce both antibody and T-cell responses, GEO-CM04S1 is being evaluated in three Phase 2 clinical trials:

As a primary vaccine for immunocompromised individuals (including post-transplant and hematologic cancer patients),
As a booster for patients with chronic lymphocytic leukemia (CLL), and
As a durable booster for healthy adults previously immunized with mRNA vaccines

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – Comstock Completes Acquisition of Haywood Quarry

Posted on October 16, 2025October 16, 2025 by [email protected]

Research News and Market Data on LODE

VIRGINIA CITY, NEVADA, October 15, 2025 — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that it has completed its purchase of the Haywood quarry industrial and mineral properties from Decommissioning Services LLC for a total of $2.2 million in cash and stock. The Haywood property totals approximately 190 acres in Lyon County, Nevada, and has available power, water, and easy access to US 50. These properties historically hosted gold mining and processing operations, and more recently, aggregate mining and are strategically located and contiguous to the Company’s Lyon County mineral properties, including our now flagship Dayton gold and silver resource.

“This is a very important addition to our mineral portfolio,” stated Mr. Corrado De Gasperis, Comstock’s Executive Chairman and CEO, “as it could conveniently host activities to support the mining at Dayton, and then provide post-mining industrial property in one of the largest industrial parks in Lyon County.”

The Comstock Lode was discovered in 1859. From 1860 to 1960, the district yielded more than eight million ounces of gold and 192 million ounces of silver, from workings greater than 3,000 feet below the surface. We have consolidated the most significant portions of the historic Comstock Lode mining district, conducted surface and airborne geophysical studies, drilled extensively, and developed detailed numerical models of the mineralization. We have secured permits, built an infrastructure, and completed two phases of test production. The Haywood Quarry is a strategic addition that enhances the efficacy of our Lyon County position.

Because of the Comstock Lode’s historical significance, the geology is well known and has been extensively studied. We have expanded our understanding of the geology through vigorous surface mapping and drill hole logging. The volume of geologic data is significant, particularly in the Lucerne and Dayton resource areas. We have accumulated a large library of historical data and detailed surface mapping of Comstock Mineral Estate properties and continue to obtain historical information from public and private sources. We have integrated this data with information obtained from our mining operations to target prospective geological exploration areas and plan exploratory drilling programs, including expanded surface and underground drilling.

The Company completed extensive geological mapping and drilling on a limited portion of our properties, particularly the Lucerne and Dayton resource areas, and characterized the mineralized material. We have performed metallurgical testing, mine planning and economic analysis while conducting extensive test mining operations, most recently from 2012 through 2016. The Company published an independent, third-party, S-K 1300 Technical Report Summary for our flagship Dayton gold and silver resources in November 2022.

The Company’s 2025 efforts include applying economic analysis to our existing gold and silver resources progressing toward preliminary economic feasibility for the southern part of the district, that is the broader Dayton resource complex, and the ultimate development of full mine and reclamation plans and the development of post productive land and community development plans.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics. To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
[email protected]

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
[email protected]

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; divestitures, spin-offs or similar distribution transactions, future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, divestitures, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Release – Titan International, Inc. to Announce Third Quarter 2025 Financial Results on November 6

Posted on October 16, 2025October 16, 2025 by [email protected]

Research News and Market Data on TWI

Oct 15, 2025

CHICAGO, Oct. 15, 2025 /PRNewswire/ — Titan International, Inc. will release its third quarter 2025 financial results before the opening of the market on Thursday, November 6, 2025 to be followed by a teleconference and webcast on Thursday, November 6, 2025 at 9:00 a.m. Eastern Time.

The real-time, listen-only webcast can be accessed using the following link https://events.q4inc.com/attendee/328660313 or on our website at www.titan-intl.com within the “Investor Relations” page under the “News & Events” menu (https://ir.titan-intl.com/news-and-events/events/default.aspx). Listeners should access the website at least 10 minutes prior to the live event.

In order to participate in the real-time teleconference, with live audio Q&A, participants should use the following dial in number:

United States (Toll-Free): 1 833 470 1428
All Other Locations: https://www.netroadshow.com/conferencing/global-numbers?confId=56511
Participants Access Code: 973752

A webcast replay of the teleconference will be available on our website (https://ir.titan-intl.com/news-and-events/events/default.aspx) soon after the live event.

About Titan : Titan International, Inc. (NYSE: TWI) is a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products. Headquartered in West Chicago, Illinois, the company globally produces a broad range of products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. For more information, visit www.titan-intl.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/titan-international-inc-to-announce-third-quarter-2025-financial-results-on-november-6-302585132.html

SOURCE Titan International, Inc.

Release – SelectQuote’s Healthcare Select Research Uncovers Critical Gaps in Care, Highlighting Urgent Need for Personalized Healthcare Solutions

Posted on October 16, 2025October 16, 2025 by [email protected]

Research News and Market Data on SLQT

10/15/2025

Nearly 70% of Served Population Face Limited Access to a Local Pharmacy

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today released a new research brief offering in-depth insights into the complex medical and social needs of the population it serves. The findings from tens of thousands of patient health needs assessments gathered by the Company’s Healthcare Select division highlight significant challenges across chronic care management, medication access, and financial security, underscoring the critical industry need for personalized, integrated healthcare solutions.

Key Research Findings:

Underserved Beneficiaries: Given that SelectQuote and Healthcare Select connect with beneficiaries telephonically, this population significantly over-indexes in historically-underserved areas lacking significant access to more traditional healthcare providers. 45% of Healthcare Select members reside in a rural zip code and 36% reside in an urban zip code, while only 11% reside in a suburban zip code.
Chronic Conditions: 74% of the population reported that they are dealing with two or more chronic conditions.
High Prescription Use: 75% of members regularly take 5 or more prescriptions.
Financial Headwinds: As 77% of SelectRx patients report annual household income of under $20,000, Social Determinants of Health often compound the treatment of health issues. 19% report having trouble accessing food on a regular basis. 36% indicate they are worried about being able to pay for bills if they were to face a serious illness.
Medication Delays: 16% of Healthcare Select members report having delayed taking medication for financial reasons.
Adherence Challenges: 40% of members have reported either forgetting to take their medications or failing to pick up prescriptions from a pharmacy. Independent studies indicate that failure to take medications consistently as prescribed (i.e., non-adherence) contributes to reduced treatment efficacy and poor disease control, higher rates of emergency department visits and hospitalizations, and increased morbidity and mortality.
Limited Pharmacy Access: Given their geographic concentration, approximately ⅔ of the population served by the Company’s SelectRx pharmacy reside in a “pharmacy desert” with limited access to local pharmacies.
Transportation: The headwinds to quality pharmacy access are exacerbated by the fact that 31% of Healthcare Select members report that they lack access to reliable transportation.

“This research provides a clear, data-driven look at the barriers to care faced by a large segment of the Medicare-eligible population,” said Bob Grant, SelectQuote President. “The high prevalence of chronic conditions, coupled with geographic and financial obstacles, illustrates why traditional one-size-fits-all healthcare is insufficient. We are committed to using this data to drive personalized solutions that effectively address these gaps.”

Mr. Grant continued, “We purpose-built Healthcare Select and our SelectRx pharmacy model to meet the needs of these underserved Medicare beneficiaries by combining telephonic outreach, personalized care coordination, direct prescription delivery, and packaging that improves adherence. By removing barriers like transportation and limited local pharmacy access, SelectRx helps patients manage complex medication regimens and improves adherence, ultimately driving better health outcomes.”

As Healthcare Select works to address members’ most pressing gaps in care — specifically in medication adherence, Social Determinants of Health, remote diagnostics and therapeutics, and chronic condition management — the Company actively seeks partners. SelectQuote invites innovative organizations and solution providers to connect with its Business Development team to collaboratively address these pressing issues impacting member care.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:
Sloan Bohlen
877-678-4083
[email protected]

Media:
Matt Gunter
913-286-4931
[email protected]

Source: SelectQuote, Inc.

Release – Nicola Mining Announces Plan for 2026 Drilling Exploration at Treasure Mountain Silver Project

Posted on October 15, 2025October 15, 2025 by [email protected]

Research News and Market Data on HUSIF

October 15, 2025 9:00 AM EDT | Source: Nicola Mining Inc.

Vancouver, British Columbia–(Newsfile Corp. – October 15, 2025) – Nicola Mining Inc. (TSXV: NIM) (OTCQB: HUSIF) (FSE: HLIA) (the “Company” or “Nicola“) is pleased to provide an update on preparation work conducted during 2025 on the Treasure Mountain Silver Project (“Treasure Mountain“) and its plan for 2026 exploration drilling program (“2026 TM Program“). The 2026 TM Program is the culmination of an airborne magnetic geophysical survey (conducted by Scott Hogg & Associates Ltd. in 2012), extensive soil sampling programs over multiple years, and 2025 field reconnaissance. Treasure Mountain is a permitted silver mine located 30 km northeast of Hope and about a 3-hour drive from Vancouver, British Columbia. Treasure Mountain was an operating mine but was put into care and maintenance in 2013^[1], due to depressed silver prices and has always been a core asset to Nicola, which has been strategically waiting for higher silver prices.

As previously announced in the Company’s June 9, 2025 news release, Nicola received a multi-year area-based exploration permit (the “MYAB Permit“), allowing the Company to conduct diamond drilling and trenching at Treasure Mountain. In addition to receipt of MYAB Permit, the Company received a ten year mine lease extension (through April 26, 2032; announced on August 30, 2024), further bolstering the attractiveness of re-opening Treasure Mountain.

The area of exploration interest is northwest of the currently suspended mine (Fig. 1) and consists of several northeast-southwest trending and steeply dipping sulphide-rich veins (Fig. 2). Photos exhibited in Figure 2 are associated with 2025 field reconnaissance focused on establishing the 2026 TM Program drill targets.

Figure 1. Geological map of Treasure Mountain showing trend of mineralized veins northeast of the mine.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4873/270388_de6ad025542159aa_001full.jpg

Initial interest in this area was driven by Coeur Mining’s (“Coeur“)^[2] (NYSE: CDE) (TSX: CDM) 2012 investment into the Company giving it a 12.7% ownership at time of investment. Coeur purchased shares at a price of $1.08 ($20.6 when considering subsequent rollbacks)^[3].

Previous exploration work along this trend is limited to six percussion holes totaling 274m in 1994 and 14 “backpack drill” holes totaling 25m in 2020. Widespread soil sampling was also conducted in 2019 and 2020. Limited rock samples were collected in 2020 and 2021. The most recent exploration along this trend (sampling conducted by Nicola in 2021) is described in Assessment Report #39721 (available on ARIS^[4]). Results from these programs are encouraging and demonstrate the presence of vein-hosted silver, copper, lead, zinc and gold. This provides support for initial diamond drilling to establish the width of the trend and mineralization at depth. Currently mineralization is present on surface and open in all directions.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/4873/270388_de6ad025542159aa_002.jpg

Figure 2. 2025 Field Reconnaissance Photos: (a) and (b) 10-20 cm wide quartz-sulphide veins steeply dipping and trending northeast-southwest. Close-ups of quartz veins show (c) mainly sphalerite with pyrite and chalcopyrite and (d) pyrite, chalcopyrite and sphalerite.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4873/270388_de6ad025542159aa_002full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/4873/270388_f8d245b9a405d91e_001.jpg

Figure 3. 3D magnetic MVI inversion at 200m depth below topography.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4873/270388_f8d245b9a405d91e_001full.jpg

Peter Espig, Chief Executive Officer, commented, “Recently we have garnered accelerated interest from both investors and strategics that have become increasingly excited about Treasure Mountain. At Nicola, we have always been aware of its significant potential, as highlighted by Coeur’s investment in the Company at a time prior to Nicola securing ownership of New Craigmont Copper Project and commencing gold production and pre-investment in Dominion Gold Project. In addition to these other projects, for the past decade we have continued to review, maintain and explore Treasure Mountain, which is more than an exploration project but is a fully permitted mine that can be reopened. We continue to review all possibilities and are excited for the 2026 TM Program.”

Qualified Person

The scientific and technical disclosures included in this news release have been reviewed and approved by Will Whitty, P.Geo., who is the Qualified Person as defined by NI 43-101. Mr. Whitty is Vice President of Exploration for the Company.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the TSX.V Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig“

Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: [email protected]
URL: www.nicolamining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

^[1] Silver prices dropped below US$20 in 2013 and reached a low of US$13.80 in December of 2015. Link
^[2] At the time of investment Coeur Mining was called Coeur d’Alene Mines Corporation
^[3] July 17, 2014 (2 for 1), June 1, 2015, (5 for 1) and November 17, 2023 (2 for 1). The first 2 rollbacks were related to a successful CCAA process.
^[4] British Columbia Geological Survey’s (BCGS) Assessment Report Indexing System

SOURCE: Nicola Mining Inc.

Release – Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Posted on October 15, 2025October 15, 2025 by [email protected]

Research News and Market Data on GYRE

October 15, 2025

PDF Version

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis.

A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is designed to evaluate the efficacy and safety of 52 weeks of Pirfenidone capsule treatment in patients with pneumoconiosis, a chronic occupational lung disease characterized by progressive pulmonary fibrosis.

Unmet Medical Need in Pneumoconiosis

Pneumoconiosis remains the most common and severe occupational disease in China, with more than 450,000 surviving patients and thousands of new cases reported each year. It results from long-term inhalation of mineral dusts such as silica or coal, which triggers persistent inflammation and progressive fibrosis of the lung tissue. Over time, this excessive scar formation causes diffuse fibrosis and irreversible loss of lung function. Despite its prevalence and severity, there is currently no approved therapy in China that specifically targets the fibrotic mechanisms underlying pneumoconiosis.

Based on recent expert consensus, China’s pneumoconiosis treatment landscape represents a significant unmet medical need, underscoring the importance of developing therapies specifically designed to slow or halt the progression of fibrosis and improve long-term outcomes for affected patients.

About the 52-Week Phase 3 Trial

The ongoing trial compares Pirfenidone 1,800 mg/day (600 mg tid) with placebo over a 52-week double-blind treatment period.

Primary Endpoint: Change from baseline in forced vital capacity (FVC) % predicted at Week 52.
Key Secondary Endpoints: Changes in diffusing capacity of the lungs for carbon monoxide (DLCO), 6-minute walk distance, St. George’s Respiratory Questionnaire (SGRQ) score, and Modified Medical Research Council (mMRC) dyspnea scale, as well as rates of acute exacerbations, hospitalizations, and deaths.
Safety Monitoring: Follows Gyre’s Development Safety Update Report (DSUR Dec 2023–Dec 2024). Most adverse events reported to date are mild to moderate, with no unexpected safety signals.
Interim Analysis: None planned.

About Pirfenidone (ETUARY®)

Pirfenidone is an oral antifibrotic small molecule that received its original approval in China in 2011 by Gyre Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF). It works by inhibiting TGF-β signaling and fibroblast proliferation. Gyre continues to advance Pirfenidone beyond IPF through multiple clinical programs, including the Phase 3 pneumoconiosis trial and the recently approved Phase 2/3 trial for oncology-related pulmonary complications such as radiation-induced lung injury (RILI) and checkpoint inhibitor pneumonitis (CIP).

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts, including Gyre’s advancement of its Phase 3 trial in China for Pirfenidone capsules for the treatment of pneumoconiosis and the initiation of Gyre’s Phase 2/3 trial in China for Pirfenidone capsules for the treatment of RILI and CIP; and trial design of Gyre’s Phase 3 trial in China for Pirfenidone capsules for the treatment of pneumoconiosis. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings with the Securities and Exchange Commission.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

For Investors:
David Zhang
[email protected]

Release – V2X Appoints Jeff Cheatham as Vice President of Contracts and Subcontracts

Posted on October 13, 2025October 13, 2025 by [email protected]

Research News and Market Data on VVX

October 13, 2025

Download(opens in new window)

RESTON, Va., Oct. 13, 2025 /PRNewswire/ — V2X, Inc. (NYSE: VVX), today announced the appointment of Jeff Cheatham as Vice President of Contracts and Subcontracts. In this role, Cheatham will oversee all contract strategy, negotiation, and administration activities across the enterprise, ensuring excellence in execution, compliance, and customer engagement in support of V2X’s global operations. He will report to V2X General Counsel, Jeremy Nance.

Cheatham brings more than 25 years of experience in federal contracting, procurement, and business leadership. He joins V2X from Peraton, where he most recently served as Vice President of Contracts. Throughout his career, he has successfully led large-scale contracts organizations, negotiated multi-billion-dollar agreements, and implemented strategic initiatives that strengthened operational performance and profitability.

“Jeff’s extensive experience and leadership in contracts and procurement make him an exceptional addition to our team,” said Jeremy Nance, General Counsel at V2X. “His proven ability to drive operational excellence and foster collaboration across complex organizations aligns perfectly with our mission to deliver trusted, innovative solutions to our customers worldwide.”

Cheatham holds a Master of Business Administration from the University of Maryland’s Robert H. Smith School of Business and a Bachelor of Science in Economics, cum laude, from George Mason University.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected]
719-637-5773

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
[email protected]
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-appoints-jeff-cheatham-as-vice-president-of-contracts-and-subcontracts-302581605.html

SOURCE V2X, Inc.

Release – V2X to Announce Third Quarter 2025 Financial Results

Posted on October 13, 2025October 13, 2025 by [email protected]

Research News and Market Data on VVX

October 13, 2025

Download(opens in new window)

RESTON, Va., Oct. 13, 2025 /PRNewswire/ — V2X, Inc., (NYSE: VVX), a leading provider of global mission solutions, will report third quarter 2025 financial results on Monday, November 3, 2025, after market close. Senior management will conduct a conference call at 4:30 p.m. ET that same day.

U.S.-based participants may dial in to the conference call at 877-300-8521, while international participants may dial 412-317-6026. A live webcast of the conference call as well as an accompanying slide presentation will be available at https://app.webinar.net/80dR21K5Yr9 and on the Investors section of the V2X website at https://gov2x.com/.

A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through November 17, 2025, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 10202916.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected]
719-637-5773

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
[email protected]
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-to-announce-third-quarter-2025-financial-results-302581312.html

SOURCE V2X, Inc.

Release – GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions

Posted on October 13, 2025October 13, 2025 by [email protected]

Research News and Market Data on GOVX

Executives to Participate at World Vaccine Congress Europe (Amsterdam, Oct 13–16) and BIO-Europe Fall (Vienna, Nov 3–5), and Meet With NGOs, Industry Partners and Academic Collaborators

ATLANTA, GA – October 13, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that senior leadership will be in Europe over the coming weeks to advance partnering and collaboration engagement across the Company’s portfolio.

Chairman & Chief Executive Officer David A. Dodd and John Sharkey, PhD, Vice President, Business Development & Executive Lead for Mpox/Smallpox, together with other members of GeoVax’s senior team, will attend and host meetings at:

World Vaccine Congress Europe 2025 – October 14–16, 2025 | Amsterdam, Netherlands
BIO-Europe 2025 Fall – November 3–5, 2025 | Vienna, Austria

In addition to conference activities, the team will conduct meetings with global NGOs, including WHO, UNICEF, CEPI, Gavi, and the Africa CDC, as well as with established and prospective academic institutional collaborators across Europe.

“We are focused on solidifying durable relationships that can accelerate development in support of expanded access to critical vaccines and immunotherapies,” said David A. Dodd, Chairman & CEO of GeoVax. “We’re engaging with global health leaders and prospective partners to align on near-term opportunities in mpox/smallpox preparedness, addressing the critically unmet needs of immunocompromised patients relative to COVID-19, expanding the development breadth of Gedeptin^® as neoadjuvant cancer therapy, and to explore complementary collaborations across our broader platform.”

Partnering Focus Areas

GeoVax will highlight opportunities spanning its pipeline and technology platforms, including (but not limited to):

GEO-MVA (Mpox/Smallpox vaccine candidate): U.S.-based MVA program designed to accelerate access to a second-source of the critically needed GEO-MVA vaccine and rapid, scalable MVA manufacturing.
GEO-CM04S1 (multi-antigen COVID-19 vaccine): Designed to elicit robust T-cell and antibody responses; partnering priorities focused on addressing the current unmet needs of an estimated over 400 million immunocompromised patients worldwide.
Gedeptin^® (gene-directed enzyme prodrug therapy): A tumor-targeted immuno-oncology approach with potential combination synergies with checkpoint inhibitors, providing a potential new neoadjuvant therapy against solid tumors.
Broader MVA platform applications: Hemorrhagic fever and Zika programs; continuous cell-line manufacturing and potential technology-transfer collaborations.

“We continue to receive compelling interest from governments, NGOs, and potential industry collaborators, seeking diversified, resilient vaccine supply and clinically differentiated immunotherapies,” added Dr. John Sharkey. “Our goal is to convert that interest into structured collaborations that accelerate development, manufacturing readiness, and regional availability.”

Request a Meeting

Organizations interested in meeting with GeoVax during WVC Europe (Amsterdam, Oct 14–16) or BIO-Europe Fall (Vienna, Nov 3–5) – or at separate times/locations in Europe – are encouraged to contact:

Business Development: [email protected]
Investor Relations: [email protected]

Additional information about GeoVax and its programs is available at www.geovax.com.

About GeoVax

Forward-Looking Statements

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]